SEC Form 4 · accession 0001683168-19-000083
Sonoma Pharmaceuticals, Inc. · SNOA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Frederick J Sandford
Officer — CEO and Interim CFO · Director
Period of report
Jan 10, 2019
Accepted (ET)
Jan 11, 2019 · 6:17 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001367083
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F1 | $0.717 | Jan 10, 2019 | A | 400,000 | A | Jul 10, 2019 | Jan 10, 2029 | Common Stock | 400,000 | 400,000 | D |
| Stock option (right to buy)F2 | $0.717 | Jan 10, 2019 | A | 50,000 | A | Jul 10, 2019 | Jan 10, 2029 | Common Stock | 50,000 | 450,000 | D |
Explanation of responses
- F1The options were granted to Mr. Sandford as an inducement stock option award in accordance with Nasdaq Listing Rule 5635(c)(4), as an inducement material to his entering into employment with the Issuer as Chief Executive Officer and Interim Chief Financial Officer.
- F2The options were granted to Mr. Sandford for his entering into employment with the Issuer as Chief Executive Officer and Interim Chief Financial Officer.